EGFR and non-small cell lung carcinoma: Unfortunately, partial patients with wild-type EGFR NSCLC could not benefit from the initial treatment with icotinib [2], and other patients with EGFR mutant NSCLC only received short-term clinical benefits from icotinib treatment [3], indicating that innate and acquired resistance limit broad application and long-term efficacy of icotinib.